• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G filed

    2/16/21 2:21:10 PM ET
    $GNMK
    Medical/Dental Instruments
    Health Care
    Get the next $GNMK alert in real time by email
    SC 13G 1 gnmk_21621.htm CONSONANCE CAPITAL MANAGEMENT LP gnmk_21621.htm
    UNITED STATES
    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549
    SCHEDULE 13G
    Under the Securities Exchange Act of 1934
    GENMARK DIAGNOSTICS INC
    (Name of Issuer)
    Common Stock, par value $0.0001 per share
    (Title of Class of Securities)
    372309104
    (CUSIP Number)
    December 31, 2020
    (Date of Event which Requires Filing of this Statement)
    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
    [X] Rule 13d-1(b)
    [   ] Rule 13d-1(c)
    [   ] Rule 13d-1(d)
    * The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.
    The information required in the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see Instructions).
    CUSIP No.: 372309104
           
    1
    NAME OF REPORTING PERSON
    Consonance Capital Management LP
    I.R.S. IDENTIFICATION NO. OF ABOVE PERSON (ENTITIES ONLY)
    2
    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP
    (a) [   ]
    (b) [   ]
    3 SEC USE ONLY
    4
    CITIZENSHIP OR PLACE OF ORGANIZATION
    Delaware USA
    NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH 5
    SOLE VOTING POWER
    6
    SHARED VOTING POWER
    4,480,163
    7
    SOLE DISPOSITIVE POWER
    8
    SHARED DISPOSITIVE POWER
    4,480,163
    9
    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
    4,480,163
    10
    CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES
    [   ]
    11
    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)
    6.25% Based on 71,721,004 shares of common stock outstanding as of October 23, 2020
    as reported in the Issuers Form 10-Q filed with the SEC on October 28, 2020.
    12
    TYPE OF REPORTING PERSON
    IA, PN
    CUSIP No.: 372309104
           
    1
    NAME OF REPORTING PERSON
    Consonance Capital Opportunity Fund Management LP
    I.R.S. IDENTIFICATION NO. OF ABOVE PERSON (ENTITIES ONLY)
    47-3018842
    2
    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP
    (a) [   ]
    (b) [   ]
    3 SEC USE ONLY
    4
    CITIZENSHIP OR PLACE OF ORGANIZATION
    Delaware USA
    NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH 5
    SOLE VOTING POWER
    6
    SHARED VOTING POWER
    1,193,518
    7
    SOLE DISPOSITIVE POWER
    8
    SHARED DISPOSITIVE POWER
    1,193,518
    9
    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
    1,193,518
    10
    CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES
    [   ]
    11
    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)
    2.04%
    12
    TYPE OF REPORTING PERSON
    IA, PN
    CUSIP No.: 372309104
           
    1
    NAME OF REPORTING PERSON
    Mitchell Blutt
    I.R.S. IDENTIFICATION NO. OF ABOVE PERSON (ENTITIES ONLY)
    2
    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP
    (a) [   ]
    (b) [   ]
    3 SEC USE ONLY
    4
    CITIZENSHIP OR PLACE OF ORGANIZATION
    USA
    NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH 5
    SOLE VOTING POWER
    6
    SHARED VOTING POWER
    6,058,505
    7
    SOLE DISPOSITIVE POWER
    8
    SHARED DISPOSITIVE POWER
    6,058,505
    9
    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
    6,058,505
    10
    CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES
    [   ]
    11
    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)
    9.99%
    12
    TYPE OF REPORTING PERSON
    HC, IN
    CUSIP No.: 372309104
           
    1
    NAME OF REPORTING PERSON
    Consonance Capman GP LLC
    I.R.S. IDENTIFICATION NO. OF ABOVE PERSON (ENTITIES ONLY)
    2
    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP
    (a) [   ]
    (b) [   ]
    3 SEC USE ONLY
    4
    CITIZENSHIP OR PLACE OF ORGANIZATION
    Delaware USA
    NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH 5
    SOLE VOTING POWER
    6
    SHARED VOTING POWER
    6,058,505
    7
    SOLE DISPOSITIVE POWER
    8
    SHARED DISPOSITIVE POWER
    6,058,505
    9
    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
    6,058,505
    10
    CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES
    [   ]
    11
    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)
    9.99%
    12
    TYPE OF REPORTING PERSON
    HC, OO
    CUSIP No.: 372309104
    ITEM 1(a). NAME OF ISSUER:
    GENMARK DIAGNOSTICS INC
    ITEM 1(b). ADDRESS OF ISSUER'S PRINCIPAL EXECUTIVE OFFICES:
    5964 La Place Court , Carlsbad, California 92008
    ITEM 2(a). NAME OF PERSON FILING:
    Consonance Capital Management LP
    Mitchell Blutt
    Consonance Capman GP LLC
    ITEM 2(b). ADDRESS OF PRINCIPAL BUSINESS OFFICE OR, IF NONE, RESIDENCE:
    1370 Avenue of the Americas
    Floor 33
    New York, NY 10019
    ITEM 2(c). CITIZENSHIP:
    Consonance Capital Management LP - Delaware USA
    Mitchell Blutt - USA
    Consonance Capman GP LLC - Delaware USA
    ITEM 2(d). TITLE OF CLASS OF SECURITIES:
    Common Stock, par value $0.0001 per share
    ITEM 2(e). CUSIP NUMBER:
    372309104
    ITEM 3. IF THIS STATEMENT IS FILED PURSUANT TO SECTION 240.13d-1(b), or 13d-2(b) or (c) CHECK WHETHER THE PERSON FILING IS A:
    (a)
    [ ]
    Broker or dealer registered under Section 15 of the Act (15 U.S.C. 78c);
    (b)
    [ ]
    Bank as defined in Section 3(a)(6) of the Act (15 U.S.C. 78c);
    (c)
    [ ]
    Insurance company as defined in Section 3(a)(19) of the Act (15 U.S.C. 78c);
    (d)
    [ ]
    Investment company registered under Section 8 of the Investment Company Act of 1940 (15 U.S.C 80a-8);
    (e)
    [X]
    An investment adviser in accordance with 240.13d-1(b)(1)(ii)(E);
    (f)
    [ ]
    An employee benefit plan or endowment fund in accordance with 240.13d-1(b)(1)(ii)(F);
    (g)
    [X]
    A parent holding company or control person in accordance with 240.13d-1(b)(1)(ii)(G);
    (h)
    [ ]
    A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
    (i)
    [ ]
    A church plan that is excluded from the definition of an investment company under Section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
    (j)
    [ ]
    A non-U.S. institution in accordance with 240.13d-1(b)(1)(ii)(J);
    (k)
    [ ]
    Group, in accordance with 240.13d-1(b)(1)(ii)(K). If filing as a non-U.S. institution in accordance with 240.13d1(b)(1)(ii)(J), please specify the type of institution:
    ITEM 4. OWNERSHIP
    (a) Amount beneficially owned:
    Consonance Capital Management LP 4,480,163
    Mitchell Blutt 4,480,163
    Consonance Capman GP LLC 4,480,163
    (b) Percent of class:
    Consonance Capital Management LP 6.25%
    Mitchell Blutt 6.25%
    Consonance Capman GP LLC 6.25%
    (c) Number of shares as to which the person has:
    (i) sole power to vote or to direct the vote:
    (ii) shared power to vote or to direct the vote:
    Consonance Capital Management LP 4,480,163
    Mitchell Blutt 4,480,163
    Consonance Capman GP LLC 4,480,163
    (iii) sole power to dispose or direct the disposition of:
    (iv) shared power to dispose or to direct the disposition of:
    Consonance Capital Management LP 4,480,163
    Mitchell Blutt 4,480,163
    Consonance Capman GP LLC 4,480,163
    ITEM 5. OWNERSHIP OF FIVE PERCENT OR LESS OF A CLASS:
    If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities, check the following [ ].
    ITEM 6. OWNERSHIP OF MORE THAN FIVE PERCENT ON BEHALF OF ANOTHER PERSON:
    The ownership information in Item 4 is incorporated herein by reference.
    ITEM 7. IDENTIFICATION AND CLASSIFICATION OF THE SUBSIDIARY WHICH ACQUIRED THE SECURITY BEING REPORTED ON BY THE PARENT HOLDING COMPANY:
    Not applicable.
    ITEM 8. IDENTIFICATION AND CLASSIFICATION OF MEMBERS OF THE GROUP:
    Not applicable.
    ITEM 9. NOTICE OF DISSOLUTION OF GROUP:
    Not applicable.
    ITEM 10. CERTIFICATION:
    By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect.
    CUSIP No.: 372309104
    SIGNATURE
    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.
    February 16 2021
    Consonance Capital Management LP
    By:
    /s/ Mitchell Blutt
    Name:
    Mitchell Blutt
    Title:
    Manager & Member
    February 16 2021
    Consonance Capital Opportunity Fund Management LP
    By:
    /s/ Mitchell Blutt
    Name:
    Mitchell Blutt
    Title:
    Manager & Member
    February 16 2021
    Mitchell Blutt
    By:
    /s/ Mitchell Blutt
    Name:
    Mitchell Blutt
    Title:
    Manager & Member
    February 16 2021
    Consonance Capman GP LLC
    By:
    /s/ Mitchell Blutt
    Name:
    Mitchell Blutt
    Title:
    Manager & Member
    Attention — Intentional misstatements or omissions of fact constitute Federal criminal violations (See 18 U.S.C. 1001).
    CUSIP No.: 372309104
    Item 4. Ownership:
    Consonance Capital Master Account LP (Consonance Master) directly holds 4,480,163 shares of the Issuers Common Stock (the Master Account Shares). Consonance Capital Management LP (the Adviser) is the investment adviser of Consonance Master, and pursuant to an investment advisory agreement (the Advisory Agreement), the Adviser exercises voting and investment power over the Master Account Shares held by Consonance Master. Consonance Capman GP LLC (Capman) is the general partner of the Adviser and Mitchell Blutt, as the Manager & Member of Capman and Chief Executive Officer of the Adviser, may be deemed to control Capman and the Adviser. Each of the Adviser, Capman and Mr. Blutt may be deeded to beneficially own the Master Account Shares, but neither the filing of this Schedule 13G nor any of its contents shall be deemed to constitute an admission that any of the Adviser, Capman or Mr. Blutt is the beneficial owner of the Master Account Shares for purposes of Section 13(d) of the Securities Exchange Act of 1934, as amended, or for any other purpose.


    EXHIBIT 99.1
    JOINT FILING AGREEMENT
    In accordance with Rule 13d-1(k)(1) under the Securities Exchange Act of 1934, as amended, the persons named below agree to the joint filing on behalf of each of them of a Statement on Schedule 13G dated February 16, 2021 (including amendments thereto) with respect to the Common Stock, par value $0.0001 per share, of GENMARK DIAGNOSTICS INC. This Joint Filing Agreement shall be filed as an Exhibit to such Statement. The undersigned acknowledge that each shall be responsible for the timely filing of any amendments to such joint filing and for the completeness and accuracy of the information concerning him or it contained herein and therein, but shall not be responsible for the completeness and accuracy of the information concerning the others.

    CONSONANCE CAPITAL MANAGEMENT LP
    By: Consonance Capman GP LLC /s/ Mitchell Blutt
    Name: Mitchell Blutt
    Title: Manager & Member

    MITCHELL BLUTT
    By: /s/ Mitchell Blutt
    Name: Mitchell Blutt
    Title: Manager & Member

    CONSONANCE CAPMAN GP LLC
    By: /s/ Mitchell Blutt
    Name: Mitchell Blutt
    Title: Manager & Member

    Get the next $GNMK alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $GNMK

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $GNMK
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Gene Panel Market size worth $ 8.22 Million, Globally, by 2028 at 21.36% CAGR: Verified Market Research®

    Jersey City, New Jersey, Oct. 13, 2021 (GLOBE NEWSWIRE) -- Verified Market Research recently published a report, "Gene Panel Market" By Technique (Amplicon-Based Approach, Hybridization-Based Approach), By Design (Predesigned Gene Panels, Customized Gene Panels), By Application (Pharmacogenetics, Diagnosis of Congenital Disorders, Cancer Risk Assessment, Others), and By Geography. According to Verified Market Research, the Global Gene Panel Market size was valued at USD 1.70 Billion in 2020 and is projected to reach USD 8.22 Billion by 2028, growing at a CAGR of 21.36% from 2021 to 2028. Download PDF Brochure: https://www.verifiedmarketresearch.com/download-sample/?rid=29123 Browse in-de

    10/13/21 11:15:00 AM ET
    $GNMK
    Medical/Dental Instruments
    Health Care

    Roche commences tender offer for all shares of GenMark Diagnostics, Inc. for $24.05 per share in cash

    Basel, 25 March 2021 – Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that it has commenced a cash tender offer for all of the outstanding shares of common stock of GenMark Diagnostics, Inc. (NASDAQ: GNMK) at a price of $24.05 per share. The tender offer is being made pursuant to the previously announced merger agreement dated as of March 12, 2021 among Roche Holdings, Inc., an indirect wholly owned subsidiary of Roche Holding Ltd, Geronimo Acquisition Corp., a wholly owned subsidiary of Roche Holdings, Inc., and GenMark. The tender offer period will expire at 12:00 midnight, Eastern Time, at the end of the day on Wednesday, April 21, 2021, unless the offer is extended. Roche

    3/25/21 12:40:00 PM ET
    $GNMK
    Medical/Dental Instruments
    Health Care

    Roche signs definitive merger agreement with GenMark Diagnostics, Inc., to access novel technology to test for broad range of pathogens with one patient sample

    Roche to acquire GenMark Diagnostics for US$ 24.05 per share with the expectation to close in the 2nd quarter of 2021GenMark provides molecular diagnostic tests that are designed to detect multiple pathogens from a single patient sampleGenMark’s ePlex platform delivers rapid and actionable results so clinicians can determine the cause of infection and the most effective treatment, potentially saving lives and alleviating the healthcare burden. The addition of GenMark’s proprietary multiplex technology complements Roche’s diagnostic offering, addressing a broad range of infectious disease testing needs, including respiratory and bloodstream infections              Basel, 15 March 2021 - Roc

    3/15/21 2:00:00 AM ET
    $GNMK
    Medical/Dental Instruments
    Health Care

    $GNMK
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    GenMark Diagnostics downgraded by BTIG

    BTIG downgraded GenMark Diagnostics from Buy to Neutral

    3/17/21 7:31:42 AM ET
    $GNMK
    Medical/Dental Instruments
    Health Care

    GenMark Diagnostics downgraded by Cowen & Co. with a new price target

    Cowen & Co. downgraded GenMark Diagnostics from Outperform to Market Perform and set a new price target of $24.05 from $23.00 previously

    3/17/21 6:46:59 AM ET
    $GNMK
    Medical/Dental Instruments
    Health Care

    GenMark Diagnostics downgraded by Canaccord Genuity

    Canaccord Genuity downgraded GenMark Diagnostics from Buy to Hold

    3/16/21 10:34:41 AM ET
    $GNMK
    Medical/Dental Instruments
    Health Care

    $GNMK
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4: Giles Lisa M. decreased direct ownership by 100% to 0 units to satisfy tax liability

    4 - GenMark Diagnostics, Inc. (0001487371) (Issuer)

    4/22/21 1:55:57 PM ET
    $GNMK
    Medical/Dental Instruments
    Health Care

    SEC Form 4: Fox James decreased direct ownership by 100% to 0 units to cover taxes

    4 - GenMark Diagnostics, Inc. (0001487371) (Issuer)

    4/22/21 1:55:12 PM ET
    $GNMK
    Medical/Dental Instruments
    Health Care

    SEC Form 4: Kagnoff Michael decreased direct ownership by 100% to 0 units to satisfy tax liability

    4 - GenMark Diagnostics, Inc. (0001487371) (Issuer)

    4/22/21 1:55:32 PM ET
    $GNMK
    Medical/Dental Instruments
    Health Care

    $GNMK
    SEC Filings

    View All

    SEC Form 15-12B filed by GenMark Diagnostics, Inc.

    15-12B - GenMark Diagnostics, Inc. (0001487371) (Filer)

    5/3/21 4:02:03 PM ET
    $GNMK
    Medical/Dental Instruments
    Health Care

    SEC Form EFFECT filed by GenMark Diagnostics, Inc.

    EFFECT - GenMark Diagnostics, Inc. (0001487371) (Filer)

    4/28/21 12:15:09 AM ET
    $GNMK
    Medical/Dental Instruments
    Health Care

    SEC Form S-8 POS filed by GenMark Diagnostics, Inc.

    S-8 POS - GenMark Diagnostics, Inc. (0001487371) (Filer)

    4/22/21 4:22:52 PM ET
    $GNMK
    Medical/Dental Instruments
    Health Care

    $GNMK
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G/A filed by GenMark Diagnostics, Inc. (Amendment)

    SC 13G/A - GenMark Diagnostics, Inc. (0001487371) (Subject)

    5/10/21 11:58:21 AM ET
    $GNMK
    Medical/Dental Instruments
    Health Care

    SEC Form SC 13G/A filed by GenMark Diagnostics, Inc. (Amendment)

    SC 13G/A - GenMark Diagnostics, Inc. (0001487371) (Subject)

    4/12/21 1:05:52 PM ET
    $GNMK
    Medical/Dental Instruments
    Health Care

    SEC Form SC 13D filed by GenMark Diagnostics, Inc.

    SC 13D - GenMark Diagnostics, Inc. (0001487371) (Subject)

    3/26/21 9:07:58 AM ET
    $GNMK
    Medical/Dental Instruments
    Health Care